Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Clinical relapse · patients with Crohn's disease (with mixed/low disease activity at baseline)

Infliximab showed no clear difference in clinical relapse (at 52 weeks, HBI > 4) compared with biosimilar (low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 1.18 [0.82, 1.69]
1 study · 155 participants
Low